$0.51
(Market cap
$1,514 Mln
Recently Viewed
Clear AllMarket cap
$1,514 Mln
Revenue (TTM)
$2,248 Mln
P/E Ratio
--
P/B Ratio
1
Div. Yield
0 %
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
$0 Mln
ROE
-0.6 %
ROCE
-- %
Industry P/E
--
EV/EBITDA
22.4
Debt to Equity
0.9
Book Value
$26.2
EPS
$-20.9
Face value
--
Shares outstanding
57,539,044
CFO
$2,249.79 Mln
EBITDA
$4,241.89 Mln
Net Profit
$1,089.42 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Enovis Corp (ENOV)
| -9.0 | 10.9 | 2.4 | -24.7 | -25.2 | -20.5 | -7.9 |
|
BSE Sensex
| -7.3 | 5.3 | -4.1 | -1.1 | 9.6 | 10.5 | 11.7 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
|---|---|---|---|
|
Enovis Corp (ENOV)
| -39.3 | -21.5 | 4.7 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Enovis Corp (ENOV)
|
24.2 | 1,514.4 | 2,248.1 | -1,184.4 | -49.5 | -58.5 | -- | 1.0 |
| 8.4 | 5,633.8 | 6,552.2 | -530.2 | -4.1 | -9.2 | -- | 1.0 | |
| 277.0 | 7,476.3 | 2,583.2 | 759.9 | 25.2 | 10.8 | 9.9 | 1.0 | |
| 39.6 | 6,195.5 | 3,436.5 | -8.6 | 2.2 | -0.4 | -- | 2.4 | |
| 122.9 | 6,939.8 | 507.4 | -187.7 | -36.2 | -26.4 | -- | 10.6 | |
| 82.1 | 5,456.9 | 1,541.6 | 233.6 | 21.6 | 21.4 | 24.6 | 5.0 | |
| 178.4 | 9,341.0 | 1,526.9 | -151.5 | 20.0 | -17.1 | 46.6 | 12.9 | |
| 333.5 | 12,941.2 | 1,403.7 | 177.7 | 14.7 | 13.8 | 73 | 9.1 | |
| 130.6 | 7,400.2 | 738.3 | 48.9 | 11.4 | 2.4 | 150.8 | 3.5 | |
| 32.7 | 14,139.4 | 6,178.4 | 626.5 | 13.0 | 11.9 | 23.2 | 2.6 |
Enovis Corporation, a medical technology company, focuses on developing clinically differentiated solutions in the United States and internationally. It operates through two segments: Prevention and Recovery, and Reconstructive segments. The... Prevention and Recovery segment offers rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, electrical stimulators for pain management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals to treat patients with musculoskeletal conditions. The Reconstructive segment develops, manufactures, markets, and distributes surgical solutions that restore mobility and improve patient outcomes, which includes a range of differentiated implants, instrumentation, and enabling technologies used in elective and non-elective joint replacement, limb reconstruction, and foot and ankle procedures; and products for the hip, knee, shoulder, elbow, extremity reconstruction and fixation, foot, ankle, and finger, as well as surgical productivity tools. It also manufactures and distributes a range of products which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company distributes its products through independent distributors, direct salespeople, and patients. The company was formerly known as Colfax Corporation. Enovis Corporation was founded in 1995 and is headquartered in Wilmington, Delaware. Read more
CEO & Chairman
Mr. Matthew L. Trerotola
CEO & Chairman
Mr. Matthew L. Trerotola
Headquarters
Wilmington, DE
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Enovis Corp (ENOV) is $24.24 (NYSE) as of 22-Apr-2026 10:43 EDT. Enovis Corp (ENOV) has given a return of -25.18% in the last 3 years.
Since, TTM earnings of Enovis Corp (ENOV) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-1.28
|
1.02
|
|
2024
|
-3.10
|
1.00
|
|
2023
|
-91.96
|
0.89
|
|
2022
|
-218.35
|
0.84
|
|
2021
|
70.19
|
1.09
|
The 52-week high and low of Enovis Corp (ENOV) are Rs 37.85 and Rs 21.15 as of 22-Apr-2026.
Enovis Corp (ENOV) has a market capitalisation of $ 1,514 Mln as on 17-Apr-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Enovis Corp (ENOV), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.